Management of Submacular Hemorrhage Using Intravitreal Brolucizumab with Pneumatic Displacement: A Case Series

We present a series of 3 cases with large fresh SMH ( ≤7 days) secondary to MNV that were treated with intravitreal injection (IVI) of brolucizumab along with SF6 gas injection. A face-down position was recommended for 5 days after the injection, with follow-up visits at regular intervals. All eyes demonstrated notable improvement in visual acuity wi th complete resolution of SMH lasting up to 6 months. There were no ocular or systemic side effects. Thus, IVI brolucizumab with SF6 gas injection is efficacious and safe for the management of large SMH secondary to MNV.Case Rep Ophthalmol 2022;13:956 –962

Source: Case Reports in Ophthalmology - November 18, 2022 Category: Opthalmology Source Type: research